2023 Independent Medical Education Request for Proposal

Issue Date: September 15, 2023

The *Independent Medical Education team at Genentech, a member of the Roche Group,* invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Request for Proposal (RFP) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech's scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech RFPs are made available through our online Genentech Funding Request System (gFRS) site (http://funding.gene.com). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (http://funding.gene.com) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this RFP will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on http://funding.gene.com)
2. This RFP does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this RFP.
4. For compliance reasons, and in fairness to all providers, all communications about this RFP must come exclusively to Genentech's department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this RFP may result in a denial.

Instructions

Eligibility Criteria	- U.S. based education provider - Registered account in gFRS - Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	Educational initiatives must be U.S.-based only

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this RFP will have 6 weeks to complete a full application. Please include "Lung RFP Sept 2023" in the title your program	October 27, 2023
Step 2	After 1 week, respective Genentech Medical Education Managers will review and provide notification of final decisions via email	November 3, 2023

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:
1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Currently Available RFP Focus Area:

Focus	Opportunity
Therapeutic Area: Oncology **Disease State:** Other **Learning Audience:** Community Medical Oncologists **Support Available:** Up to $250,000	Lung cancer is the most common cause of cancer related deaths worldwide, and an estimated 1.7 million people die of this disease each year. Approximately 85% of tumors are diagnosed as non-small cell lung cancer (NSCLC). Lung cancer is recognized as a heterogeneous disease at the molecular level, and this classification informs our overall understanding of its underlying biology and clinical behavior as well as therapeutic decision-making. Biomarker testing has been a key tool in precision medicine when determining therapeutic options and further subclassification of the disease e.g. epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), rearranged during transfection (RET), the mesenchymal-epithelial transition (MET), and neurotrophic tropomyosin tyrosine kinase (NTRK) non small cell lung cancer. ALK-positive lung cancer represents about 4% of lung cancer and generally appears in adenocarcinoma non-small cell lung cancer. Patients who are ALK-positive tend to be younger than the average lung cancer patient. They also tend not to have a smoking history. About half of all people with early lung cancer (45-76%, depending on disease stage) still experience a cancer recurrence following surgery, despite adjuvant chemotherapy. Recent treatment innovations, including immunotherapies, have improved the outlook for some patients with early-stage NSCLC. Genentech is seeking medical education to address knowledge gaps around the recent advances made in NSCLC subclassifications and targeted therapies. **References:** 1. Yang SR, Schultheis AM, Yu H, Mandelker D, Ladanyi M, Büttner R. Precision medicine in non-small cell lung cancer: Current applications and future directions. Semin Cancer Biol. 2022 Sep;84:184-198. doi: 10.1016/j.semcancer.2020.07.009. Epub 2020 Jul 27. PMID: 32730814. 2. ALK and Lung Cancer. American Lung Association. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/alk-lung-cancer